Latest Pyrimidines Stories

Early clinical observations in the fungal meningitis outbreak A new article being published early online in Annals of Internal Medicine describes the diagnosis and treatment protocol established in a Roanoke, Va. hospital to care for dozens of patients presenting with suspected fungal meningitis related to contaminated epidural spinal injections. This unprecedented surge of patients seeking care for a rare central nervous system (CNS) infection required physicians to react quickly with...

MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported interim results from the Phase I/II study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, which were included in an abstract submitted to the American Society of Hematology in August 2012. Updated results will be presented in an Oral Session at the 2012...

WAYNE, N.J., Oct. 23, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery. The results showed the CHEST-1 study met its primary endpoint by demonstrating a statistically significant improvement in the six-minute walk distance (6MWD). In the...

WAYNE, N.J., Oct. 22, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid. The study met its primary endpoint by demonstrating a statistically significant improvement in the six-minute walk distance (6MWD) with patients...

WAYNE, N.J., Oct. 17, 2012 /PRNewswire/ -- Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 - 25, in Atlanta, GA. Data from two pivotal, Phase III trials researching riociguat in patients with for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) will...

MISSISSAUGA, ON, Oct. 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today announced that the results of its Phase I/II Study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, have been selected by the ASH Program Committee for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology to be held in...

- Completed dosing for 166 patient CYT387 Phase I/II nine-month trial - - Completed enrolment of 61 patient CYT387 Phase II BID trial - MISSISSAUGA, ON, Sept. 21, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported operational and financial results for its 2012 fiscal year, ended June 30, 2012. "We made significant progress with CYT387 during Fiscal 2012, highlighted by...

MORRIS PLAINS, N.J., May 17, 2012 /PRNewswire/ -- Bill Rancic*, an American entrepreneur, motivational speaker and star of the hit reality show, Giuliana & Bill, has teamed up with ROGAINE® to serve as the brand's first-ever "Growth Coach®." In this new role, Rancic, an avid user of Men's ROGAINE® Unscented Foam, the #1 dermatologist recommended brand for hair regrowth, will share his personal story to help empower men to take control of their hair loss and build confidence...

MIAMI BEACH, Fla., May 16, 2012 /PRNewswire/ -- Divine Skin Inc. (OTCBB: DSKX), a leading developer of personal-care products, announced results for its quarter ending March 31, 2012. Net revenue was $1.98 million, compared to $2.25 million in the same quarter of 2011. Gross margin improved significantly, to more than 50 percent or $1.05 million, comparable to last year's quarterly result of $1.10 million. Net loss for the quarter was $428,000, compared to $192,000 for the first...

Results of study using animal model among the presentations at the meeting Experimental Biology 2012 Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the...